209 related articles for article (PubMed ID: 35853537)
1. miR-495-3p regulates sphingolipid metabolic reprogramming to induce Sphk1/ceramide mediated mitophagy and apoptosis in NSCLC.
Arora S; Singh P; Tabassum G; Dohare R; Syed MA
Free Radic Biol Med; 2022 Aug; 189():71-84. PubMed ID: 35853537
[TBL] [Abstract][Full Text] [Related]
2. Up-regulation and tumor-promoting role of SPHK1 were attenuated by miR-330-3p in gastric cancer.
Wang Z; Qu H; Gong W; Liu A
IUBMB Life; 2018 Nov; 70(11):1164-1176. PubMed ID: 30281914
[TBL] [Abstract][Full Text] [Related]
3. A Rheostat of Ceramide and Sphingosine-1-Phosphate as a Determinant of Oxidative Stress-Mediated Kidney Injury.
Ueda N
Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409370
[TBL] [Abstract][Full Text] [Related]
4. Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug.
Guillermet-Guibert J; Davenne L; Pchejetski D; Saint-Laurent N; Brizuela L; Guilbeau-Frugier C; Delisle MB; Cuvillier O; Susini C; Bousquet C
Mol Cancer Ther; 2009 Apr; 8(4):809-20. PubMed ID: 19372554
[TBL] [Abstract][Full Text] [Related]
5. LncRNA HULC promotes non-small cell lung cancer cell proliferation and inhibits the apoptosis by up-regulating sphingosine kinase 1 (SPHK1) and its downstream PI3K/Akt pathway.
Liu L; Zhou XY; Zhang JQ; Wang GG; He J; Chen YY; Huang C; Li L; Li SQ
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8722-8730. PubMed ID: 30575912
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotective role of sphingolipid rheostat in excitotoxic retinal ganglion cell death.
Nakamura N; Honjo M; Yamagishi R; Kurano M; Yatomi Y; Watanabe S; Aihara M
Exp Eye Res; 2021 Jul; 208():108623. PubMed ID: 34022173
[TBL] [Abstract][Full Text] [Related]
7. Targeting SPHK1/PBX1 Axis Induced Cell Cycle Arrest in Non-Small Cell Lung Cancer.
Lin Z; Li Y; Han X; Fu Z; Tian Z; Li C
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361531
[TBL] [Abstract][Full Text] [Related]
8. Ginsenoside compound K inhibits angiogenesis via regulation of sphingosine kinase-1 in human umbilical vein endothelial cells.
Shin KO; Seo CH; Cho HH; Oh S; Hong SP; Yoo HS; Hong JT; Oh KW; Lee YM
Arch Pharm Res; 2014; 37(9):1183-92. PubMed ID: 24687256
[TBL] [Abstract][Full Text] [Related]
9. SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism.
Maceyka M; Sankala H; Hait NC; Le Stunff H; Liu H; Toman R; Collier C; Zhang M; Satin LS; Merrill AH; Milstien S; Spiegel S
J Biol Chem; 2005 Nov; 280(44):37118-29. PubMed ID: 16118219
[TBL] [Abstract][Full Text] [Related]
10. [Sphingosine kinase 1 and tumor].
Zhang CX; He HW; Shao RG
Yao Xue Xue Bao; 2013 Jul; 48(7):971-8. PubMed ID: 24133963
[TBL] [Abstract][Full Text] [Related]
11. Targeting sphingosine kinase 1/2 by a novel dual inhibitor SKI-349 suppresses non-small cell lung cancer cell growth.
Xue Y; Jiang K; Ou L; Shen M; Yang Y; Lu J; Xu W
Cell Death Dis; 2022 Jul; 13(7):602. PubMed ID: 35831279
[TBL] [Abstract][Full Text] [Related]
12. LncRNA PSMG3AS1 promotes proliferation of non-small cell lung cancer cells by sponging miR-613 to upregulate SphK1.
Shen W; Hong X; Jin C; Xi Y
Cell Cycle; 2021 May; 20(9):829-838. PubMed ID: 33849377
[TBL] [Abstract][Full Text] [Related]
13. Sphingosine kinase inhibitors decrease viability and induce cell death in natural killer-large granular lymphocyte leukemia.
LeBlanc FR; Liu X; Hengst J; Fox T; Calvert V; Petricoin EF; Yun J; Feith DJ; Loughran TP
Cancer Biol Ther; 2015; 16(12):1830-40. PubMed ID: 26252351
[TBL] [Abstract][Full Text] [Related]
14. Targeting SphK1 as a new strategy against cancer.
Shida D; Takabe K; Kapitonov D; Milstien S; Spiegel S
Curr Drug Targets; 2008 Aug; 9(8):662-73. PubMed ID: 18691013
[TBL] [Abstract][Full Text] [Related]
15. Sphingosine kinase-1 enhances resistance to apoptosis through activation of PI3K/Akt/NF-κB pathway in human non-small cell lung cancer.
Song L; Xiong H; Li J; Liao W; Wang L; Wu J; Li M
Clin Cancer Res; 2011 Apr; 17(7):1839-49. PubMed ID: 21325072
[TBL] [Abstract][Full Text] [Related]
16. Oxidative stress-dependent sphingosine kinase-1 inhibition mediates monoamine oxidase A-associated cardiac cell apoptosis.
Pchejetski D; Kunduzova O; Dayon A; Calise D; Seguelas MH; Leducq N; Seif I; Parini A; Cuvillier O
Circ Res; 2007 Jan; 100(1):41-9. PubMed ID: 17158340
[TBL] [Abstract][Full Text] [Related]
17. MiR-34b-3p represses cell proliferation, cell cycle progression and cell apoptosis in non-small-cell lung cancer (NSCLC) by targeting CDK4.
Feng H; Ge F; Du L; Zhang Z; Liu D
J Cell Mol Med; 2019 Aug; 23(8):5282-5291. PubMed ID: 31199581
[TBL] [Abstract][Full Text] [Related]
18. [The effect and mechanism of sphingosine kinase-1 knockdown on non-small cell lung cancer cell proliferation and mitochondrial apoptotic pathway].
Cao YH; Yin W; Lyu YR
Sheng Li Xue Bao; 2021 Dec; 73(6):893-900. PubMed ID: 34961863
[TBL] [Abstract][Full Text] [Related]
19. A metabolic shift favoring sphingosine 1-phosphate at the expense of ceramide controls glioblastoma angiogenesis.
Abuhusain HJ; Matin A; Qiao Q; Shen H; Kain N; Day BW; Stringer BW; Daniels B; Laaksonen MA; Teo C; McDonald KL; Don AS
J Biol Chem; 2013 Dec; 288(52):37355-64. PubMed ID: 24265321
[TBL] [Abstract][Full Text] [Related]
20. Impact of Sphingolipid Mediators on the Determination of Cochlear Survival in Ototoxicity.
Tabuchi K; Hara A
Curr Mol Pharmacol; 2018; 11(4):279-284. PubMed ID: 29766830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
